Trial
NCT02691182
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Supernus Pharmaceuticals, Inc.
Collaborators
—
Condition
Attention Deficit Hyperactivity Disorder (ADHD)
Intervention
SPN-810
Why stopped
The program was shut down due to a lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-16